SUNNYVALE, Calif., March 2, 2015 /PRNewswire/ -- Accuray
Incorporated (Nasdaq: ARAY) announced today that the first patient
treatment has been completed using the CyberKnife® M6™
System with the InCise™ Multileaf Collimator (MLC). The treatment
was administered as a multidisciplinary effort between Dr.
Steven Burton from the Department of
Radiation Oncology and Dr. Johnathan
Engh from the Department of Neurosurgery at UPMC in
Pittsburgh, Pennsylvania. UPMC was
one of the InCise MLC evaluation sites working in collaboration
with Accuray.
"We have successfully treated the first patient using the
CyberKnife M6 System with the InCise MLC. The patient, diagnosed
with a brain meningioma, was a typical candidate for highly-focused
treatment that can be delivered by the CyberKnife," said Dr.
Dwight E. Heron MD, FACRO, FACR,
Director of Radiation Services. "With the addition of the MLC, we
were able to achieve equivalent precision in tumor targeting and
sparing of healthy tissue, but it took us less than half the time –
just under 22 minutes – to complete a traditional one hour
treatment. The treatment time includes continuous imaging
throughout the procedure to ensure accurate dose delivery and the
actual time spent delivering the radiation. This real-world case is
consistent with our InCise MLC technical evaluation experience and
exceeded our expectations in its efficiency."
The M6 Series delivers radiosurgery and stereotactic body
radiation therapy, enabling precise, high-quality dose
distributions to be confidently administered to the patient with
extreme accuracy over a minimum number of treatments, reducing side
effects and preserving patients' quality of life. The system is
able to adjust and automatically stay on target in real-time,
accounting for patient and tumor motion. CyberKnife is the only
robotic radiosurgery system available today which delivers such
high precision treatments for intra- and extra-cranial disease
sites throughout the body.
"We congratulate Dr. Heron, Dr. Huq and their team on treating
the first patient using the CyberKnife M6 System and InCise MLC,"
said Joshua H. Levine, president and
chief executive officer of Accuray. "With the addition of the MLC,
clinicians can deliver the same precise radiosurgery treatments
they have come to expect with the CyberKnife System, while
significantly reducing treatment times, for a wider range of tumor
types, including larger and different kinds of tumors than were
previously treated."
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company
that develops, manufactures and sells precise, innovative tumor
treatment solutions that set the standard of care with the aim of
helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to advantages of new
technology, clinical applications, clinical results, patient
outcomes, successful adoption of Accuray technologies, and
Accuray's leadership position in radiation oncology innovation and
technologies. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially
from expectations, including but not limited to the risks detailed
under the heading "Risk Factors" in the company's report on Form
10-K, filed on August 29, 2014, the
company's reports on Form 10-Q, filed on November 7, 2014 and February 6, 2015, and the company's other filings
with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/first-patient-treatment-with-the-cyberknife-m6-system-and-the-incise-multileaf-collimator-has-been-completed-300043146.html
SOURCE Accuray Incorporated